3.3(top 10%)
2-year impact
1.4K(top 20%)
PR articles
30.5K(top 10%)
PR citations
77(top 10%)
PR h-index
83(top 10%)
h-index
3.2(top 10%)
2-YI (no self-cite.)
1.6K
documents
37.9K
doc citations

Top Articles

#TitleJournalYearCitations
1What are biomarkers?Current Opinion in HIV and AIDS20101,256
2Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globeCurrent Opinion in HIV and AIDS2016306
3Contribution of sexually transmitted infections to the sexual transmission of HIVCurrent Opinion in HIV and AIDS2010237
4HIV subtype diversity worldwideCurrent Opinion in HIV and AIDS2019237
5Long-acting injectable antiretrovirals for HIV treatment and preventionCurrent Opinion in HIV and AIDS2013214
6HIV treatment as prevention and HPTN 052Current Opinion in HIV and AIDS2012202
7Microbial translocation and microbiome dysbiosis in HIV-associated immune activationCurrent Opinion in HIV and AIDS2016199
8The global epidemic of HIV infection among men who have sex with menCurrent Opinion in HIV and AIDS2009180
9HIV epidemics among transgender womenCurrent Opinion in HIV and AIDS2014170
10Tissue reservoirs of HIVCurrent Opinion in HIV and AIDS2016170
11Biomarkers of immune dysfunction in HIVCurrent Opinion in HIV and AIDS2010155
12Evolving epidemiology of HIV-associated malignanciesCurrent Opinion in HIV and AIDS2017155
13Formulation and pharmacology of long-acting cabotegravirCurrent Opinion in HIV and AIDS2015151
14The biology of CCR5 and CXCR4Current Opinion in HIV and AIDS2009150
15HIV/hepatitis C coinfection natural history and disease progressionCurrent Opinion in HIV and AIDS2011149
16Persistent HIV-1 replication during antiretroviral therapyCurrent Opinion in HIV and AIDS2016145
17HIV infection among female sex workers in concentrated and high prevalence epidemicsCurrent Opinion in HIV and AIDS2014143
18Role of acute and early HIV infection in the sexual transmission of HIVCurrent Opinion in HIV and AIDS2010141
19The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuitCurrent Opinion in HIV and AIDS2011138
20Tenofovir and bone healthCurrent Opinion in HIV and AIDS2016137
21Current concepts for PrEP adherence in the PrEP revolutionCurrent Opinion in HIV and AIDS2016133
22Human papillomavirus-related disease in people with HIVCurrent Opinion in HIV and AIDS2009130
23The global epidemiology of adolescents living with HIVCurrent Opinion in HIV and AIDS2018128
24The interplay between HIV and COVID-19: summary of the data and responses to dateCurrent Opinion in HIV and AIDS2021125
25Th17 cytokines in mucosal immunity and inflammationCurrent Opinion in HIV and AIDS2010124
26HIV-1-specific antibody responses during acute and chronic HIV-1 infectionCurrent Opinion in HIV and AIDS2009123
27Epidemiology and clinical characteristics of elite controllersCurrent Opinion in HIV and AIDS2011122
28The mucosal barrier and immune activation in HIV pathogenesisCurrent Opinion in HIV and AIDS2008121
29Epidemiology of HIV-associated tuberculosisCurrent Opinion in HIV and AIDS2009120
30Shocking HIV out of hidingCurrent Opinion in HIV and AIDS2016118
31Retention and adherenceCurrent Opinion in HIV and AIDS2018116
32The role of healthcare providers in the roll out of preexposure prophylaxisCurrent Opinion in HIV and AIDS2016115
33Kaposi sarcoma herpesvirus-associated cancers and related diseasesCurrent Opinion in HIV and AIDS2017115
34HIV and ageingCurrent Opinion in HIV and AIDS2016113
35Genital inflammation, immune activation and risk of sexual HIV acquisitionCurrent Opinion in HIV and AIDS2016113
36Residual inflammation and viral reservoirsCurrent Opinion in HIV and AIDS2016112
37Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineCurrent Opinion in HIV and AIDS2010111
38Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and updateCurrent Opinion in HIV and AIDS2010109
39Th17 and regulatory T cells: implications for AIDS pathogenesisCurrent Opinion in HIV and AIDS2010109
40The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM)Current Opinion in HIV and AIDS2015108
41Lenacapavir: a first-in-class HIV-1 capsid inhibitorCurrent Opinion in HIV and AIDS2022107
42Where does HIV hide? A focus on the central nervous systemCurrent Opinion in HIV and AIDS2013106
43Overcoming pharmacologic sanctuariesCurrent Opinion in HIV and AIDS2013106
44Cell-to-cell HIV-1 spread and its implications for immune evasionCurrent Opinion in HIV and AIDS2009104
45HIV broadly neutralizing antibody targetsCurrent Opinion in HIV and AIDS2015103
46Concentrated HIV subepidemics in generalized epidemic settingsCurrent Opinion in HIV and AIDS2014100
47Th17 cell dynamics in HIV infectionCurrent Opinion in HIV and AIDS201099
48Histone deacetylase inhibitors and HIV latencyCurrent Opinion in HIV and AIDS201199
49Quality and quantityCurrent Opinion in HIV and AIDS201299
50HIV treatment cascade in MSM, people who inject drugs, and sex workersCurrent Opinion in HIV and AIDS201598